Skip to content

Released Feb 28, 2024, after the close

10-K filed Mar 1, 2024, 61 days after period end · 0000950170-24-023845

Q4 2023 · 10-K

derived · Computed from the longer spans the company filed.

Revenue$28.19Mderived+4.3% vs Q4 2022+11.1% vs Q3 2023
Net Income-$19.78MderivedN/M vs Q4 2022N/M vs Q3 2023
EPS, diluted—Not derived. Share counts vary by quarter.
Gross Profitderived$13,413,000—
Operating Incomederived-$21,386,000N/M
Operating Cash Flowderived-$14,061,000N/M
Free Cash Flowderived-$14,139,000N/M
Margins · derived
Gross margin47.6%
Operating margin-75.9%+2.3 pt vs Q4 2022
Net margin-70.2%+7.0 pt vs Q4 2022

What the release said

The release

Same quarter

MetricQ4 2023derived from reported figuresQ4 2022derived from reported figuresQ4 2021derived from reported figuresQ4 2020
Revenue$28.19M$27.02M$38.27M$44.61M
Net Income-$19.78M-$20.85M-$9.43M-$18.03M
EPS Diluted———-$0.24

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Standard Biotools Inc. · CIK 1162194 · Engraved from SEC EDGAR